Jun 8, 2022· Comment from Association for Accessible Medicines (AAM)· FDA-2022-N-0075-0009
FDA, The Association for Accessible Medicines (AAM) appreciates the opportunity to submit comments on the draft guidance, "FDA Quality Metrics Reporting Program; Establishment of a Public Docket; Request for Comments" (Docket No. FDA-2022-N-0075). Please find attached AAM's comments and supporting materials on this draft guidance. Thanks, Scott Kuzner, Ph.D. Senior Director, Sciences and Regulatory Affairs Association for Accessible Medicines (AAM)